Medtech Talk
Episode: 179 - Overcoming Valuation Overhang – Implications on Raising Capital and Exits
How has the bullishness of 2016-2022 impacted public markets and private companies? In this special episode of Medtech Talk, we share Geoff Pardo’s Medtech MVP 2023 panel, featuring Tak G Cheung, Partner at New Enterprise Associates; J.P. Peltier, Managing Director of Global Head, Healthcare Investment Banking at Piper Sandler; Michael Ryan, VP of Venture Capital & Business Development at Boston Scientific Corp; Gwen Watanabe, Managing Director at H.I.G. Capital; and Rob Winklemann, Managing Partner & CEO at Credo 180. The panelists discuss the implications for private companies, particularly those that were financed during the boom times, as well as strategies for keeping private companies financed, and the outlook for liquidity via M&A or IPO.
How has the bullishness of 2016-2022 impacted public markets and private companies? In this special episode of Medtech Talk, we share Geoff Pardo’s Medtech MVP 2023 panel, featuring Tak G Cheung, Partner at New Enterprise Associates; J.P. Peltier, Managing Director of Global Head, Healthcare Investment Banking at Piper Sandler; Michael Ryan, VP of Venture Capital & Business Development at Boston Scientific Corp; Gwen Watanabe, Managing Director at H.I.G. Capital; and Rob Winklemann, Managing Partner & CEO at Credo 180. The panelists discuss the implications for private companies, particularly those that were financed during the boom times, as well as strategies for keeping private companies financed, and the outlook for liquidity via M&A or IPO.